Jens Panse

9.5k total citations · 1 hit paper
154 papers, 2.2k citations indexed

About

Jens Panse is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Jens Panse has authored 154 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Immunology, 55 papers in Hematology and 34 papers in Genetics. Recurrent topics in Jens Panse's work include Complement system in diseases (43 papers), Blood groups and transfusion (19 papers) and Renal Diseases and Glomerulopathies (15 papers). Jens Panse is often cited by papers focused on Complement system in diseases (43 papers), Blood groups and transfusion (19 papers) and Renal Diseases and Glomerulopathies (15 papers). Jens Panse collaborates with scholars based in Germany, United States and France. Jens Panse's co-authors include Carsten Bokemeyer, Alexander Röth, Britta Höchsmann, Nicolaus Kröger, Djordje Atanackovic, Morag Griffin, Jeff Szer, Rosa Nguyen, Tim Luetkens and Temitayo Ajayi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Jens Panse

139 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021 249 citations Peter Hillmen, Jeff Szer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jens Panse Germany	25	917	705	441	407	360	154	2.2k
Kasiani C. Myers United States	30	1.4k 1.5×	1.1k 1.5×	328 0.7×	262 0.6×	496 1.4×	149	3.0k
David Hagerty United States	19	1.6k 1.7×	627 0.9×	380 0.9×	340 0.8×	412 1.1×	34	4.2k
D. Close United States	15	1.2k 1.3×	442 0.6×	362 0.8×	548 1.3×	237 0.7×	26	3.0k
Anna Gayà Spain	21	1.1k 1.2×	655 0.9×	235 0.5×	506 1.2×	495 1.4×	51	2.1k
María Galindo-Izquierdo Spain	30	853 0.9×	238 0.3×	478 1.1×	134 0.3×	516 1.4×	114	2.6k
Anne Huynh France	28	359 0.4×	1.6k 2.3×	593 1.3×	499 1.2×	625 1.7×	130	2.7k
Hans‐Peter Tony Germany	32	2.1k 2.3×	803 1.1×	866 2.0×	660 1.6×	438 1.2×	151	4.4k
Shigeto Tohma Japan	33	968 1.1×	408 0.6×	354 0.8×	317 0.8×	578 1.6×	182	3.5k
Chunde Bao China	31	905 1.0×	305 0.4×	217 0.5×	283 0.7×	483 1.3×	107	2.7k
Paul Browne Ireland	26	1.5k 1.6×	1.3k 1.9×	457 1.0×	956 2.3×	858 2.4×	68	3.7k

Countries citing papers authored by Jens Panse

Since Specialization

Citations

This map shows the geographic impact of Jens Panse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Panse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Panse more than expected).

Fields of papers citing papers by Jens Panse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Panse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Panse. The network helps show where Jens Panse may publish in the future.

Co-authorship network of co-authors of Jens Panse

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Panse. A scholar is included among the top collaborators of Jens Panse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Panse. Jens Panse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panse, Jens, et al.. (2025). Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria. Hämostaseologie. 45(2). 166–174.

Rogg, Manuel, Eva L. Decker, Martin Pöhl, et al.. (2025). Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Clinical Investigation. 135(13). 2 indexed citations

Cosson, Valérie, Rong Fu, Austin Kulasekararaj, et al.. (2025). Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria. British Journal of Clinical Pharmacology. 91(5). 1479–1490.

Lang, Fabian, Andreas Voß, Guido Kobbe, et al.. (2025). Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma. 66(6). 1079–1087.

Griffin, Morag, Richard J. Kelly, Jens Panse, et al.. (2024). Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Advances. 8(7). 1776–1786. 19 indexed citations

Piatek, Caroline, Jong Wook Lee, Morag Griffin, et al.. (2024). Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial. Blood. 144(Supplement 1). 2692–2692. 1 indexed citations

Büsch, Andreas, Andrea Hartmann, Marina Noris, et al.. (2024). Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity. Frontiers in Immunology. 15. 1383123–1383123. 5 indexed citations

Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB^high cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations

Jacobs, Bénédikt, Christoph Kahl, Christian Koenecke, et al.. (2024). Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients. European Journal Of Haematology. 112(4). 641–649.

10.

Dingli, David, Carlos de Castro, Austin Kulasekararaj, et al.. (2024). Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 29(1). 2329030–2329030. 7 indexed citations

11.

Panse, Jens, Koo Wilson, Jesse Fishman, et al.. (2023). Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal Of Haematology. 111(1). 72–83. 4 indexed citations

12.

Mause, Erica R. Vander, Jillian M. Baker, Sabarinath Venniyil Radhakrishnan, et al.. (2023). Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Science Translational Medicine. 15(705). eadd7900–eadd7900. 17 indexed citations

13.

Teschner, Daniel, Jens Panse, Jan‐Hendrik Naendrup, et al.. (2023). Chlorhexidine gluconate‐coated gel pad dressings for prevention of central venous catheter‐related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry‐based matched‐pair analysis. European Journal Of Haematology. 111(6). 914–921. 1 indexed citations

14.

Panse, Jens, Jan‐Hendrik Naendrup, Martin Schmidt‐Hieber, et al.. (2022). Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-study. Annals of Hematology. 101(10). 2317–2324. 4 indexed citations

15.

Latour, Régis Peffault de, Jeff Szer, Ilene C. Weitz, et al.. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet Haematology. 9(9). e648–e659. 43 indexed citations

16.

Birndt, Sebastian, Thomas Schenk, Frank M. Brunkhorst, et al.. (2020). Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Journal of Cancer Research and Clinical Oncology. 146(4). 1065–1077. 69 indexed citations

17.

Vieri, Margherita, Martin Kirschner, Mareike Tometten, et al.. (2020). Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita. International Journal of Molecular Sciences. 21(19). 7196–7196. 18 indexed citations

18.

Frobel, Joana, Michael Lenz, Peter Uciechowski, et al.. (2017). Leukocyte Counts Based on DNA Methylation at Individual Cytosines. Clinical Chemistry. 64(3). 566–575. 18 indexed citations

19.

Richter, Anna, Weibo Kong, Mohamed Hamed, et al.. (2017). Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells. Blood. 130. 3887–3887. 1 indexed citations

20.

Schrezenmeier, Hubert, Peter Bettelheim, Jens Panse, et al.. (2012). Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian Consensus1). LaboratoriumsMedizin. 35(6). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact